BR112022008683A2 - Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax - Google Patents

Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax

Info

Publication number
BR112022008683A2
BR112022008683A2 BR112022008683A BR112022008683A BR112022008683A2 BR 112022008683 A2 BR112022008683 A2 BR 112022008683A2 BR 112022008683 A BR112022008683 A BR 112022008683A BR 112022008683 A BR112022008683 A BR 112022008683A BR 112022008683 A2 BR112022008683 A2 BR 112022008683A2
Authority
BR
Brazil
Prior art keywords
navitoclax
mpn
myelofibrosis
treatment
related disorders
Prior art date
Application number
BR112022008683A
Other languages
English (en)
Portuguese (pt)
Inventor
Hayslip John
Holes Leanne
Mensing Sven
Nuthalapati Silpa
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of BR112022008683A2 publication Critical patent/BR112022008683A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022008683A 2019-11-05 2020-11-04 Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax BR112022008683A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930951P 2019-11-05 2019-11-05
US202062984518P 2020-03-03 2020-03-03
PCT/US2020/058910 WO2021092030A1 (en) 2019-11-05 2020-11-04 Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Publications (1)

Publication Number Publication Date
BR112022008683A2 true BR112022008683A2 (pt) 2022-07-19

Family

ID=73449255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008683A BR112022008683A2 (pt) 2019-11-05 2020-11-04 Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax

Country Status (13)

Country Link
US (2) US11285159B2 (zh)
EP (1) EP4054585A1 (zh)
JP (1) JP2022553820A (zh)
KR (1) KR20220098755A (zh)
CN (1) CN115279375A (zh)
AU (1) AU2020378279A1 (zh)
BR (1) BR112022008683A2 (zh)
CA (1) CA3160091A1 (zh)
CL (1) CL2022001177A1 (zh)
DO (1) DOP2022000095A (zh)
IL (1) IL292713A (zh)
MX (1) MX2022005375A (zh)
WO (1) WO2021092030A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160091A1 (en) * 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7713170B2 (en) 2006-07-31 2010-05-11 Hyundai Motor Company Shift control method of automatic transmission
US20080193943A1 (en) 2006-09-05 2008-08-14 Abbott Laboratories Companion diagnostic assays for cancer therapy
US20080233567A1 (en) 2006-09-05 2008-09-25 Murray William E Companion diagnostic assays for cancer therapy
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
US20100087436A1 (en) 2006-11-16 2010-04-08 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20100028889A1 (en) 2006-12-04 2010-02-04 Abbott Laboratories Companion diagnostic assays for cancer therapy
BRPI0719563A2 (pt) 2006-12-04 2013-12-10 Abbott Lab Ensaios diagnósticos amigáveis para terapia de câncer
WO2008082673A2 (en) 2006-12-28 2008-07-10 Abbott Laboratories Companion diagnostic assays for cancer therapy
WO2009064938A1 (en) 2007-11-16 2009-05-22 Abbott Laboratories Method of treating arthritis
EP2219651A1 (en) 2007-12-06 2010-08-25 Abbott Laboratories Oral compositions of abt-263 for treating cancer
US8277804B2 (en) 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US20190083665A1 (en) 2008-11-25 2019-03-21 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
EP2361095B1 (en) 2008-11-25 2017-12-20 AlderBio Holdings LLC Antagonists of il-6 to raise albumin and/or lower crp
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
KR20120052937A (ko) 2009-06-18 2012-05-24 아보트 러보러터리즈 안정한 나노입자형 약물 현탁액
NZ598461A (en) 2009-09-20 2013-12-20 Abbvie Inc Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
JP5779591B2 (ja) 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド Ａｂｔ−２６３カプセル剤
SG182016A1 (en) 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
SG10201805807PA (en) 2012-06-26 2018-08-30 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
HUE040126T2 (hu) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
KR20150140685A (ko) 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
US20160045531A1 (en) 2013-03-14 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
BR112015029969A2 (pt) 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
WO2015095834A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
CA3100140C (en) 2014-01-28 2023-10-24 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
JP2017532312A (ja) 2014-09-17 2017-11-02 エピザイム，インコーポレイティド 癌を治療するための併用療法
MX2018004207A (es) * 2015-10-09 2018-07-06 Boehringer Ingelheim Int Nuevos compuestos de espiro[3h-indol-3,2â´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
RU2769527C2 (ru) 2016-06-22 2022-04-01 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
US10668078B2 (en) 2016-07-28 2020-06-02 Children's Hospital Medical Center Methods and compositions for treating mesothelioma and small lung cancer that express midkine
CN106177955B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
KR20190110128A (ko) 2017-02-03 2019-09-27 에이아이 테라퓨틱스, 인코포레이티드 Hsp90 억제제를 사용하여 암을 치료하는 방법
TR201703149A2 (tr) 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
US20200281925A1 (en) 2017-03-31 2020-09-10 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
EP3612181A4 (en) * 2017-04-21 2021-01-06 Epizyme, Inc. COMBINATION THERAPIES WITH EHMT2 INHIBITORS
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
US11317646B2 (en) 2018-08-18 2022-05-03 Louis Dischler Methods and compositions for rapidly decreasing epigenetic age and restoration of more youthful function
US20220031685A1 (en) 2018-09-18 2022-02-03 Signalchem Lifesciences Corporation Combination therapy for treating blood cancer
WO2020092117A2 (en) 2018-10-30 2020-05-07 Unity Biotechnology, Inc. Killing senescent cells and treating senescence-associated diseases or disorders using a combination of a bcl inhibitor and an mcl-1 inhibitor
US20220054606A1 (en) 2018-12-19 2022-02-24 University Of Maryland, Baltimore Asparaginase-induced glutamine depletion combined with bcl-2 inhibition for treatment of hematologic and solid cancers
AU2019400980A1 (en) 2018-12-20 2021-06-24 Novartis Ag Pharmaceutical combinations
MA56206A (fr) 2019-06-12 2022-04-20 Juno Therapeutics Inc Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie
CA3160091A1 (en) * 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Also Published As

Publication number Publication date
US20210128573A1 (en) 2021-05-06
DOP2022000095A (es) 2022-07-31
EP4054585A1 (en) 2022-09-14
MX2022005375A (es) 2022-10-07
CL2022001177A1 (es) 2023-01-20
JP2022553820A (ja) 2022-12-26
CA3160091A1 (en) 2021-05-14
US20230019186A1 (en) 2023-01-19
WO2021092030A1 (en) 2021-05-14
US11285159B2 (en) 2022-03-29
CN115279375A (zh) 2022-11-01
KR20220098755A (ko) 2022-07-12
AU2020378279A1 (en) 2022-05-26
IL292713A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
GT201700246A (es) Métodos y kits para tratar la depresión
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
BR112017008093A2 (pt) processos para tratamento de doenças oculares
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112017001420A2 (pt) método
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
BR112018002550A2 (pt) mecanismo de resistência a inibidores do bromodomínio de bet
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
PH12019500422A1 (en) Methods and composition for the prediction of the activity of enzastaurin
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
BR112018074152A8 (pt) Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
BR112019009771A2 (pt) ligação de anticorpos especificamente à cd66c e utilização dos mesmos
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
BR112023020182A2 (pt) Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
BR112019016839A2 (pt) tratamentos de combinação que compreendem a administração de 1h-pirazolo[4,3-b] piridinas
BR112022008683A2 (pt) Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112018013847A2 (pt) métodos para administrar a angiotensina ii
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ